Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| I3Y-MC-JPCU | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Business decision based on the inability to enroll subjects into the trial
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Abemaciclib + Fulvestrant | Experimental | 150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle. |
|
| Standard Chemotherapy | Active Comparator | Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Abemaciclib | Drug | Administered orally |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) | ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to the corresponding treatment arm [intent-to-treat (ITT) population], based on investigator-assessed tumor responses.CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking in reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Confirmations of CR and PR are not required. | Randomization to Measured Progressive Disease (Up to 12 Months) |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival (PFS) | PFS is defined as the time from first dose date until the first occurrence of documented disease progression per Response Criteria In Solid Tumors version 1.1(RECIST v1.1) or death from any cause in the absence of progressive disease. Progression-free survival will be based on investigator-assessed tumor responses; there will not be an independent central review of imaging data. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scottsdale Healthcare Hospitals | Avondale | Arizona | 85392 | United States | ||
| University of Arizona Cancer Center |
Not provided
| Label | URL |
|---|---|
| A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer | View source |
Not provided
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Participants who have had at least one adequate tumor assessment at baseline and post-baseline and are off study treatment are considered to have completed the study.
The study was terminated early as a business decision based on the inability to enroll subjects into the trial.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Abemaciclib + Fulvestrant | 150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle. |
| FG001 | Standard Chemotherapy |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 20, 2020 | Jun 29, 2021 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fulvestrant | Drug | Administered IM |
|
| Standard Chemotherapy | Drug | Standard chemotherapy of physician's choice administered according to product label. |
|
|
| First Dose Date to Objective Progression or Death Due to Any Cause (Up to 12 Months) |
| Time to Response (TTR) | TTR is defined as the time from first dose date until the date that measurement criteria for CR or PR (whichever is first recorded) are first met, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. | First Dose to Date of CR or PR (Up to 12 Months) |
| Duration of Response (DoR) | DoR is defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. | Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Up to 12 Months) |
| Progression Free Survival 2 (PFS 2) | PFS 2 is defined as the time from first dose date to the disease progression date on next line (first line of post-discontinuation treatment), or starting date of the second line of post-discontinuation treatment or death from any cause, whichever is earlier, or death from any cause, whichever is earlier. | Randomization to Second Objective Progression or Death Due to Any Cause (Up to 12 Months) |
| Phoenix |
| Arizona |
| 85004 |
| United States |
| Yuma Regional Cancer Center | Yuma | Arizona | 85364 | United States |
| CARTI Cancer Center | Little Rock | Arkansas | 72205 | United States |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | United States |
| Compassionate Cancer Care Medical Group Inc | Corona | California | 92879 | United States |
| Chan Soon- Shiong Institute for Medicine | Costa Mesa | California | 92627 | United States |
| Chan Soon- Shiong Institute for Medicine | El Segundo | California | 90245 | United States |
| Compassionate Cancer Care Medical Group Inc | Fountain Valley | California | 92708 | United States |
| St. Joseph Heritage Healthcare | Fullerton | California | 92835 | United States |
| Scripps Clinic | La Jolla | California | 92037 | United States |
| UCLA Medical Center | Los Angeles | California | 90024 | United States |
| TRIO - Translational Research in Oncology-US, Inc. | Los Angeles | California | 90095 | United States |
| Univ of California Irvine College of Medicine | Orange | California | 92868 | United States |
| Comprehensive Cancer Centers of the Desert | Palm Springs | California | 92262 | United States |
| Desert Hematology Oncology Medical Group | Rancho Mirage | California | 92270 | United States |
| Emad Ibrahim, MD, INC | Redlands | California | 92373 | United States |
| Compassionate Cancer Care Medical Group Inc | Riverside | California | 92501 | United States |
| University of California, Davis - Health Systems | Sacramento | California | 95864 | United States |
| Torrance Memorial Medical Center | Torrance | California | 90505 | United States |
| Banner MD Anderson Cancer Center | Greeley | Colorado | 80631 | United States |
| Hartford Hospital | Hartford | Connecticut | 06102-5037 | United States |
| Millennium Oncology | Hollywood | Florida | 33024 | United States |
| Ocala Oncology, P.A. | Ocala | Florida | 34474 | United States |
| Tallahassee Memorial Cancer Center | Tallahassee | Florida | 32308 | United States |
| Cleveland Clinic of Florida | Weston | Florida | 33331 | United States |
| Candler Medical Oncology Practice | Savannah | Georgia | 31405 | United States |
| Tift Regional Health System Anita Stewart Oncology Center | Tifton | Georgia | 31794 | United States |
| Kaiser Permanente Center for Health Research | Honolulu | Hawaii | 96819 | United States |
| Saint Alphonsus Regional Medical Center | Boise | Idaho | 83706 | United States |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | United States |
| Touro Infirmary | New Orleans | Louisiana | 70115 | United States |
| Willis-Knighton Cancer Center | Shreveport | Louisiana | 71103 | United States |
| York Hospital | York Village | Maine | 03909 | United States |
| Reliant Medical Group, Inc. | Worcester | Massachusetts | 01608 | United States |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | United States |
| Baptist Cancer Center | Oxford | Mississippi | 38655 | United States |
| St. Francis Medical Center | Grand Island | Nebraska | 68803 | United States |
| Oncology Hematology West | Omaha | Nebraska | 68130 | United States |
| OptumCare Cancer Care | Las Vegas | Nevada | 89102 | United States |
| Carol Simon Cancer Center at Overlook Medical Center | Summit | New Jersey | 07901 | United States |
| Brooklyn Methodist Hospital | Brooklyn | New York | 11215 | United States |
| Weill Cornell Medical College | New York | New York | 10065 | United States |
| SUNY At Stony Brook | Stony Brook | New York | 11794 | United States |
| White Plains Hospital | White Plains | New York | 10601 | United States |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | United States |
| Cancer Care Associates of York | York | Pennsylvania | 17403 | United States |
| Womens and Infants | Providence | Rhode Island | 02905 | United States |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | United States |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | United States |
| Oncology Consultants, P.A. | Houston | Texas | 77030 | United States |
| Renovatio Clinical | The Woodlands | Texas | 77380 | United States |
| University of Vermont Medical Center | Burlington | Vermont | 05401 | United States |
| Providence Regional Cancer Partnership | Everett | Washington | 98201 | United States |
| Cancer Care Northwest | Spokane | Washington | 99202 | United States |
| Centro Integrado de Cancer del Sur, PSC | Coto Laurel | PR | 00780 | Puerto Rico |
| Bella Vista Oncology Group | Mayagüez | PR | 00680 | Puerto Rico |
| Ponce Medical School | Ponce | PR | 00716 | Puerto Rico |
| Centro de Cancer de la Mujer | Ponce | PR | 00717 | Puerto Rico |
| Fundacion de Investigacion de Diego | San Juan | PR | 00927 | Puerto Rico |
| Clinical Research Puerto Rico, Inc. | San Juan | 00909 | Puerto Rico |
Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label. |
| Received Any Quantity of Study Treatment |
|
| COMPLETED |
|
| NOT COMPLETED |
|
All randomized participants.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Abemaciclib + Fulvestrant | 150 mg Abemaciclib given orally BID with 500 mg fulvestrant given by IM injection on C1D1 and C1D15, then Day 1 of each subsequent cycle. |
| BG001 | Standard Chemotherapy | Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants | No |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants | No |
| |||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants | No |
| |||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants | No |
| |||||||||||||||||
| Region of Enrollment | Count of Participants | Participants | No |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) | ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to the corresponding treatment arm [intent-to-treat (ITT) population], based on investigator-assessed tumor responses.CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking in reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Confirmations of CR and PR are not required. | All randomized participants. | Posted | Number | percentage of participants | Randomization to Measured Progressive Disease (Up to 12 Months) |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Progression Free Survival (PFS) | PFS is defined as the time from first dose date until the first occurrence of documented disease progression per Response Criteria In Solid Tumors version 1.1(RECIST v1.1) or death from any cause in the absence of progressive disease. Progression-free survival will be based on investigator-assessed tumor responses; there will not be an independent central review of imaging data. | Zero participants analyzed, no data collected. | Posted | First Dose Date to Objective Progression or Death Due to Any Cause (Up to 12 Months) |
|
| ||||||||||||||||||||||||||||||||
| Secondary | Time to Response (TTR) | TTR is defined as the time from first dose date until the date that measurement criteria for CR or PR (whichever is first recorded) are first met, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. | Zero participants analyzed, no data collected. | Posted | First Dose to Date of CR or PR (Up to 12 Months) |
|
| ||||||||||||||||||||||||||||||||
| Secondary | Duration of Response (DoR) | DoR is defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. | Zero participants analyzed, no data collected. | Posted | Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Up to 12 Months) |
|
| ||||||||||||||||||||||||||||||||
| Secondary | Progression Free Survival 2 (PFS 2) | PFS 2 is defined as the time from first dose date to the disease progression date on next line (first line of post-discontinuation treatment), or starting date of the second line of post-discontinuation treatment or death from any cause, whichever is earlier, or death from any cause, whichever is earlier. | Zero participants analyzed, no data collected. | Posted | Randomization to Second Objective Progression or Death Due to Any Cause (Up to 12 Months) |
|
|
Baseline up to 12 months
All randomized participants who received any quantity of study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Abemaciclib + Fulvestrant | 150 mg Abemaciclib given orally BID with 500 mg fulvestrant given by IM injection C1D1 and C1D15, then Day 1 of each subsequent cycle. | 1 | 1 | 1 | 1 | 1 | 1 |
| EG001 | Standard Chemotherapy | Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label. | 1 | 3 | 0 | 3 | 3 | 3 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dehydration | Metabolism and nutrition disorders | MedDRA 23.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Dry eye | Eye disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Eye irritation | Eye disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Lacrimation increased | Eye disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Swelling of eyelid | Eye disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Hypoaesthesia oral | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Oral pain | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Mucosal inflammation | General disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Mucosal pigmentation | General disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Peripheral swelling | General disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Abscess jaw | Infections and infestations | MedDRA 23.1 | Systematic Assessment |
| |
| Clostridium difficile infection | Infections and infestations | MedDRA 23.1 | Systematic Assessment |
| |
| Limb injury | Injury, poisoning and procedural complications | MedDRA 23.1 | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Blood alkaline phosphatase increased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Blood calcium decreased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Lymphocyte count decreased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Platelet count decreased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| White blood cell count decreased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Depressed level of consciousness | Nervous system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Hyperaesthesia | Nervous system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Neuropathy peripheral | Nervous system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Seizure | Nervous system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Taste disorder | Nervous system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Chronic kidney disease | Renal and urinary disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Dysuria | Renal and urinary disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Micturition urgency | Renal and urinary disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Pollakiuria | Renal and urinary disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Dysphonia | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Upper-airway cough syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Skin exfoliation | Skin and subcutaneous tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA 23.1 | Systematic Assessment |
|
This study was terminated early as a business decision based on the inability to enroll subjects into the trial.
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Medical Officer | Eli Lilly and Company | 800-545-5979 | ClinicalTrials.gov@lilly.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jul 26, 2019 | Jun 29, 2021 | SAP_001.pdf |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000590451 | abemaciclib |
| D000077267 | Fulvestrant |
| D000069287 | Capecitabine |
| D000077143 | Docetaxel |
| D013660 | Taxes |
| D017239 | Paclitaxel |
| ID | Term |
|---|---|
| D004958 | Estradiol |
| D004963 | Estrenes |
| D004962 | Estranes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D045166 | Estradiol Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D003841 | Deoxycytidine |
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D005472 | Fluorouracil |
| D014498 | Uracil |
| D011744 | Pyrimidinones |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D004224 | Diterpenes |
| D013729 | Terpenes |
| D004467 | Economics |
| D004472 | Health Care Economics and Organizations |
Not provided
Not provided
| >=65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|